Naviter Wealth LLC Purchases 1,210 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Naviter Wealth LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 54.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 3,433 shares of the medical research company’s stock after purchasing an additional 1,210 shares during the period. Naviter Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,997,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Northwest Financial Advisors acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. True Wealth Design LLC grew its stake in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after acquiring an additional 51 shares during the last quarter. Pineridge Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $39,000. Cape Investment Advisory Inc. boosted its stake in Thermo Fisher Scientific by 52.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after purchasing an additional 26 shares in the last quarter. Finally, Raleigh Capital Management Inc. increased its stake in Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and set a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research report on Tuesday. Barclays reduced their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, HSBC increased their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $606.47.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $7.79 on Tuesday, reaching $533.93. The company’s stock had a trading volume of 1,315,042 shares, compared to its average volume of 1,549,184. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $203.81 billion, a P/E ratio of 34.32, a PEG ratio of 2.58 and a beta of 0.77. The stock has a 50-day moving average price of $574.71 and a 200-day moving average price of $563.50. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.